Sirtex Medical announces collaboration update with OncoSec Medical
News provided by
Share this article
TAVO™ for the treatment of advanced melanoma
WOBURN, Mass., Jan. 19, 2021 /PRNewswire/
Sirtex Medical US Holdings, Inc. ( Sirtex ), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec s lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO™ and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec.
Share this article
Share this article
PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 /PRNewswire/ OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec ) today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company s lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug/device combination products, as well as their established oncology sales force in the U.S.
Daniel O Connor, President and Chief Executive Officer of OncoSec, stated, Sirtex is a strong company with significant experience in the sales and marketing of drug/device combination products to treat cancer. This deal provides OnocSec with the potential to commercialize TAVO with a highly skilled U.S. sales force in this